ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 813

Monocyte and Macrophage Transcriptional Phenotypes in Systemic Juvenile Idiopathic Arthritis Reveal TRIM8 as a Mediator of IFNγ Hyperresponsiveness and Risk for Macrophage Activation Syndrome

Grant Schulert1, Thuy Do 1, Sanjeev Dhakal 1, Ndate Fall 2, Mario Medvedovich 3, Sherry Thornton 1, Nathan salomonis 2 and Alexei A. Grom 1, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3University of Cincinnati College of Medicine, Cincinnati, OH

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: interferons and Gene Expression, macrophage activation syndrome, Systemic JIA

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S077: Pediatric Rheumatology – Basic Science (810–814)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe and distinct subtype of childhood arthritis. Children with SJIA are at risk for macrophage activation syndrome (MAS), a life-threatening episode of hyperinflammation driven by interferon-gamma (IFNγ). Previous work has suggested that monocytes in SJIA display hyperresponsiveness to IFNγ, but the molecular basis of this remains unclear. The objective of this study is to identify monocyte and macrophage polarization phenotypes including features of interferon response.

Methods: Bulk RNA-sequencing (RNA-seq) was performed on purified monocytes from 26 patients with SJIA without overt MAS. In addition, single-cell RNA-seq was performed on isolated bone marrow macrophages (BMM). THP-1 monocytic cells were transfected with TRIM8-specific small-interfering RNA (siRNA) prior to stimulation with IFNγ.

Results: Bulk RNA-seq of purified SJIA monocytes revealed marked transcriptional changes between cells from patients with high vs low serum ferritin levels including upregulated gene pathways Response to External Stimulus (p=2.73×10-17) Defense Response (p=2.66×10-14), and Inflammatory Response (p=1.95×10-11). When comparing the SJIA monocyte signature to well-characterized polarization phenotypes, we identified little evidence of IFNγ-induced signature but substantial overlap with multiple polarization states, reflecting either a mixed phenotype or multiple distinct cell populations. Interestingly, among the most highly upregulated genes in SJIA monocytes was tripartite motif containing 8 (TRIM8), an E3 ubiquitin-ligase involved in activation of IFNγ through promoting degradation of the suppressor of cytokine signaling 1 (SOCS1). Elevated TRIM8 expression was found in monocytes from both active and inactive SJIA patients, with the highest levels in those with subclinical MAS (n=3). Furthermore, we utilized scRNA-seq to determine gene expression profiles of BMM from a patient with subclinical MAS. This single cell approach identified a distinct subpopulation of BMM which exhibited markedly altered transcriptional profiles, with the most significantly upregulated pathways being cellular response to IFNγ (p=1.35e-14), endocytic vesicle membranes (p=8.44E-14), and phagosome (p=2.98e-9). These BMM also showed significantly increased expression of TRIM8 (6.4-fold), IFNAR1 (10.5-fold), and IFNGR2 (13.8-fold). To confirm the role of TRIM8 in augmenting macrophage responses to IFNγ, TRIM8 expression was knocked-down in THP-1 using siRNA. TRIM8 knock-down macrophages showed significant reductions in both early (4 hour) and late (24-48 hours) response to IFNγ, as determined by production of CXCL9, a biomarker for MAS activity in both mouse models and patients.

Conclusion: Peripheral monocytes in SJIA display markers of multiple polarization states, while during MAS BMM demonstrate a clear IFNγ response phenotype. TRIM8 is highly expressed in both monocytes and macrophages in SJIA, and in vitro knockdown of TRIM8 reduces macrophage IFNγ response. These data provide a molecular mechanism for monocyte hyperresponsiveness to IFNγ in SJIA, as well as a novel therapeutic target for MAS.


Disclosure: G. Schulert, Novartis, 5, 8; T. Do, None; S. Dhakal, None; N. Fall, None; M. Medvedovich, None; S. Thornton, None; N. salomonis, None; A. Grom, AB2 Bio Ltd, 2, 5, AB2Bio, 2, 5, Children's Hospital Medical Center, 3, Novartis, 2, 5, Novartis Pharmaceuticals Corporation, 2, 5, Novartis Pharmaceuticals Corporations, 5, NovImmune, 2, 5, Novimmune, 2, 5.

To cite this abstract in AMA style:

Schulert G, Do T, Dhakal S, Fall N, Medvedovich M, Thornton S, salomonis N, Grom A. Monocyte and Macrophage Transcriptional Phenotypes in Systemic Juvenile Idiopathic Arthritis Reveal TRIM8 as a Mediator of IFNγ Hyperresponsiveness and Risk for Macrophage Activation Syndrome [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/monocyte-and-macrophage-transcriptional-phenotypes-in-systemic-juvenile-idiopathic-arthritis-reveal-trim8-as-a-mediator-of-ifn%ce%b3-hyperresponsiveness-and-risk-for-macrophage-activation-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/monocyte-and-macrophage-transcriptional-phenotypes-in-systemic-juvenile-idiopathic-arthritis-reveal-trim8-as-a-mediator-of-ifn%ce%b3-hyperresponsiveness-and-risk-for-macrophage-activation-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology